Cambiogenplasmid

Cambiogenplasmid

Gene therapy
Target gene	VEGF
Vector	Plasmid
Clinical data
Trade names	Neovasculgen
Other names	Pl-VEGF165
Routes of administration	Intraneural injection
ATC code	V03AX ( WHO )
Identifiers
CAS Number	1540077-18-6
ChemSpider	none

Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF). ^{[1] [2]} Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF. ^{[3] [4]} It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.

Cambiogenplasmid formulation was invented and developed by Dr. Zagit Gaymalov in Dr. Alexander Kabanov's lab at the University of Nebraska Medical Center in 2005. Dr. Kabanov and his team demonstrated that certain block copolymers could induce transient plasmid expression in muscle tissue for up to a month. ^[5]

Inspired by this discovery, Dr. Gaymalov, then a graduate student, explored its potential for clinical applications, focusing on prolonged gene expression. One of the most pressing medical challenges at the time was hind-limb ischemia, a condition with significant unmet clinical needs and no pharmacological treatments available beyond surgery or amputation. Under the guidance of Dr. Irving Zucker and Dr. Maram Reddy, Dr. Gaymalov developed a murine model to replicate hind-limb ischemia conditions.

The initial formulation consisted of a plasmid encoding VEGF 165 under the CMV promoter, combined with the non-ionic carrier SP1017, composed of two amphiphilic block copolymers (Pluronics L61 and F127). In 2006, this work earned a pre-doctoral fellowship from the American Heart Association and led to multiple publications. ^[6] By 2011, the exact formulation received approval for clinical use in Russia.

References

1. "Vascular endothelial growth factor gene therapy - HSCI". Adis Insight. Springer Nature Switzerland AG.
2. "Gene Therapy for PAD Approved". Drug Discovery and Development. 6 December 2011. Archived from the original on 3 September 2015. Retrieved 5 August 2015.
3. "Neovasculogen listing in Eurolab". Eurolab. Retrieved 4 August 2015.
4. Deev RV, Bozo IY, Mzhavanadze ND, Voronov DA, Gavrilenko AV, Chervyakov YV, et al. (September 2015). "pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia". Journal of Cardiovascular Pharmacology and Therapeutics. 20 (5): 473–82. doi:10.1177/1074248415574336. PMID   25770117. S2CID   13443907.
5. Gaymalov, Zagit. "American Heart Association Pre-doctoral Fellowship". American Heart Association.
6. Gaymalov, Zagit. "American Heart Association Pre-doctoral Fellowship". American Heart Association.

See also

• Therapeutic angiogenesis